Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2-associated high-risk HER2-negative early breast cancer: updated results from the OlympiA phase III trial
Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2-associated high-risk HER2-negative early breast cancer: updated results from the OlympiA phase III trial. // Annals of Oncology. – URL: https://www.sciencedirect.com/science/article/pii/S0923753426014560?dgcid=rss_sd_all
Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2-associated high-risk HER2-negative early breast cancer: updated results from the OlympiA phase III trial. Annals of Oncology. https://www.sciencedirect.com/science/article/pii/S0923753426014560?dgcid=rss_sd_all
“Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2-associated high-risk HER2-negative early breast cancer: updated results from the OlympiA phase III trial.” Annals of Oncology.
@article{article35966,
title = {Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2-associated high-risk HER2-negative early breast cancer: updated results from the OlympiA phase III trial},
journal = {Annals of Oncology},
url = {https://www.sciencedirect.com/science/article/pii/S0923753426014560?dgcid=rss_sd_all}
}